Fathi, A., Perl, A., Fell, G., Jonas, B., Ragon, B., Mims, A., Borate, U., Mannis, G., Quillen, K., Stahl, M., Koller, P., Artz, A., Malki, M. M. A., Marcucci, G., Peters, M. L., Graubert, T., Westervelt, P., Amrein, P., Hock, H., Brunner, A., Hobbs, G., Narayan, R., Lee, M., Aubrey, B., Watson, A., Hao, R., Dhaver, S., Grunwald, M., Chen, Y., Matthews, A., Hourigan, C., Wood, B., Neuberg, D., El-Jawahri, A., Aldoss, I. (2025). Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia. Blood. https://doi.org/10.1182/blood-2025-6